Research programme: calcitonin gene-related peptide receptor antagonists - Merck

Drug Profile

Research programme: calcitonin gene-related peptide receptor antagonists - Merck

Alternative Names: CGRP receptor antagonists - Merck; Imidazoazepanes - Merck; MK 8031; MK-2918; MK-8825

Latest Information Update: 09 Jul 2015

Price : $50

At a glance

  • Originator Merck & Co
  • Class Piperidines; Small molecules; Spiro compounds
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Migraine

Most Recent Events

  • 09 Jul 2015 Merck enters into an agreement with Allergan for the divestiture of MK 8031
  • 07 Jul 2015 Merck plans a phase II study for Migraine
  • 07 Jul 2015 Preclinical development is underway in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top